HomeCompareERFSF vs JNJ

ERFSF vs JNJ: Dividend Comparison 2026

ERFSF yields 0.95% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ERFSF wins by $3.79M in total portfolio value
10 years
ERFSF
ERFSF
● Live price
0.95%
Share price
$72.07
Annual div
$0.68
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.81M
Annual income
$3,165,047.99
Full ERFSF calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — ERFSF vs JNJ

📍 ERFSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodERFSFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ERFSF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ERFSF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ERFSF
Annual income on $10K today (after 15% tax)
$80.44/yr
After 10yr DRIP, annual income (after tax)
$2,690,290.79/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, ERFSF beats the other by $2,689,587.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ERFSF + JNJ for your $10,000?

ERFSF: 50%JNJ: 50%
100% JNJ50/50100% ERFSF
Portfolio after 10yr
$1.91M
Annual income
$1,582,937.88/yr
Blended yield
82.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ERFSF
Analyst Ratings
2
Buy
1
Hold
1
Sell
Consensus: Buy
Altman Z
3.1
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ERFSF buys
0
JNJ buys
0
No recent congressional trades found for ERFSF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricERFSFJNJ
Forward yield0.95%3.36%
Annual dividend / share$0.68$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR100%5.8%
Portfolio after 10y$3.81M$20.0K
Annual income after 10y$3,165,047.99$827.78
Total dividends collected$3.73M$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: ERFSF vs JNJ ($10,000, DRIP)

YearERFSF PortfolioERFSF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,889$189.26$10,676$355.77+$213.00ERFSF
2$12,037$385.22$11,407$389.39+$630.00ERFSF
3$13,675$795.90$12,198$426.53+$1.5KERFSF
4$16,323$1,690.18$13,056$467.62+$3.3KERFSF
5$21,236$3,770.81$13,987$513.12+$7.2KERFSF
6$31,892$9,169.90$14,998$563.56+$16.9KERFSF
7$59,866$25,740.99$16,098$619.52+$43.8KERFSF
8$154,372$90,315.65$17,295$681.69+$137.1KERFSF
9$600,488$435,309.98$18,599$750.82+$581.9KERFSF
10$3,807,570$3,165,047.99$20,022$827.78+$3.79MERFSF

ERFSF vs JNJ: Complete Analysis 2026

ERFSFStock

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. It operates approximately 900 laboratories in 54 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.

Full ERFSF Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this ERFSF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ERFSF vs SCHDERFSF vs JEPIERFSF vs OERFSF vs KOERFSF vs MAINERFSF vs ABBVERFSF vs MRKERFSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.